Abstract:Background: Coronavirus disease 19 (COVID-19) caused by a novel coronavirus (2019-nCoV) has now been classified as a pandemic by the World Health Organization (WHO). It has been reported that 2019-nCoV could be detected in various human secreta and excreta such as sputum, faeces and urine. However, the detection of 2019-nCoV in saliva has not been reported to date. To provide a more comprehensive understanding of the effects of 2019-nCoV on oral health and possible saliva transmission, the expression of the putative ACE2 (angiotensin-converting enzyme II) receptor of 2019-nCoV in salivary gland epithelial cells were analyzed in bulk RNA-seq proﬁles from public databases. Additionally, to evaluate the oral health status of COVID-19 patients, a questionnaire survey on oral-related symptoms of COVID-19 patients was performed. Methods: To analyze ACE2 expression in salivary glands, bulk RNA-seq proﬁles from four public datasets including GTEx dataset, HPA dataset, FANTOM5 dataset and Consensus dataset were collected. Altogether, 31 COVID-19 patients were recruited, whose 2019-nCoV nucleic acid detection remained positive before or on the day of sample collection. Of these 31 patients, there were 4 critically-ill cases whereby oropharyngeal swabs were tested positive. Saliva was collected from the opening of the salivary gland canal of cleaned oral cavity to avoid contamination by other secretions from the respiratory tract. At the same time, oropharyngeal swabs were also collected. Then the presence of 2019-nCoV nucleic acids in saliva was detected by RT-PCR. Additionally, a questionnaire survey on various oral symptoms such as dry mouth and amblygeustia was also carried out on COVID-19 patients. Findings: ACE2 expression was present at detectable levels in the salivary glands. Interestingly, we found 4 cases with positive detection of 2019-nCoV nucleic acid in saliva. It is worth noting that 3 cases with positive detection in saliva were critically-ill patients on ventilator support, thus implying a high potential (75%) for detection of 2019-nCoV in the saliva of critically-ill patients. At the same time, the two major oral-related symptoms, dry mouth (46.3%) and amblygeustia (47.2%), were manifested by a relatively high proportion of 108 COVID-19 patients. Interpretation: This study thus confirms the expression of ACE2 in the salivary glands, and demonstrates the possibility of 2019-nCoV infection of the salivary glands. The reason that the positive saliva detection rate was as high as 75% (3/4) in critically-ill patients in our study might be due to virus invasion caused by high viral loads or destroyed salivary glands at the late stage of the disease. The emergence of viral particles in the saliva might be an indication that the disease condition of the patient has deteriorated and progressed to the terminal stage. Hence, saliva may be a new source of diagnostic specimens for critically-ill patients, since it can be easily collected without any invasive procedures.The two major oral-related symptoms, dry mouth and amblygeustia, were manifested by a relatively high proportion of COVID-19 patients suggesting that oral symptoms can also be considered as initial symptoms of COVID-19 infection. Funding Statement: None. Declaration of Interests: The authors declare no competing interests. Ethics Approval Statement: This study was approved by the Medical Ethics Committee of Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (20200062).

Saliva for diagnosis of SARS‐CoV‐2: First report from India

Role of Saliva as a Non-Invasive Diagnostic Method for Detection of COVID-19

Saliva as an Alternative Specimen for Molecular COVID-19 Testing in Community Settings and Population-Based Screening

Saliva as a Biological Fluid in SARS-CoV-2 Detection

Evaluation of Self-collected Saliva Samples Without Viral Transport Media for SARS-CoV-2 Testing via RT-PCR and Comparison of Amplicon Sequences Against Commonly Used Primers in Diagnostic Assays

Saliva sample for detection of SARS-CoV-2: A possible alternative for mass testing

SARS-CoV-2 and Saliva as a Diagnostic Tool: A Real Possibility

Sensitive detection and quantification of SARS-CoV-2 in saliva

Conventional Naso-Oropharyngeal Sampling Versus Self-Collected Saliva Samples in COVID-19 Testing

Diagnostic Performance and Tolerability of Saliva and Nasopharyngeal Swab Specimens in the Detection of SARS-CoV-2 by RT-PCR

Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2

Detection of SARS-CoV-2 in saliva: implications for specimen transport and storage

Comparison of saliva with oral and nasopharyngeal swabs for SARS‐CoV‐2 detection on various commercial and laboratory‐developed assays

RT-PCR/MALDI-TOF mass spectrometry-based detection of SARS-CoV-2 in saliva specimens

Saliva as a testing specimen with or without pooling for SARS-CoV-2 detection by multiplex RT-PCR test

Detection of SARS-CoV-2 Specific Antibodies in Saliva Samples

Evaluating and optimizing Acid-pH and Direct Lysis RNA extraction for SARS-CoV-2 RNA detection in whole saliva

Detection of SARS‐CoV‐2 in saliva and characterization of oral symptoms in COVID‐19 patients

SARS-CoV-2 Detection via RT-PCR in Matched Saliva and Nasopharyngeal Samples Reveals High Concordance in Different Commercial Assays

Detection of 2019-nCoV in Saliva and Characterization of Oral Symptoms in COVID-19 Patients

Saliva as a Potential Specimen to Monitor IL-6, TNF-α and IL-10 in COVID-19 Patients